1031 KB47 KB200520252022Morgan, Tinaštevilka:2letnik:73str. 95-106COBISSID_HOST:140694275ISSN:2536-4316URN:URN:NBN:SI:doc-DDYAGSUDslSlovensko farmacevtsko društvoFarmacevtski vestnikanti-inflammatory medicationsantiviral medicationsCovid-19Protivirusna zdravilaProtivnetna zdravilaSARS-CoV (virus)SARS-CoV-2Terapija z zdraviliZdravljenje koronavirusne bolezni 19 z zdravili| Overview of COVID-19 therapeutics|The underlying pathophysiologic evolution of the disease from the predominantly viral infection-driven phase to the late, immune-mediated phase is important in the assessment of the role of medications against COVID-19. The best results can be expected from the orally used nirmatrelvir coformulated with ritonavir, the intravenously used remdesivir and the anti-SARS-CoV-2 monoclonal antibodies. The oral antiviral molnupiravir is less effective. When treating the fully developed disease, the most widely tested medications are dexamethasone and tocilizumab. Other anti-inflammatory treatments, baricitinib, tofacitinib or anakinra, have been shown to express very good clinical endpoints, which were however proven in a single clinical trial. The virus mutating to a variant less likely to cause typical presentation with severe immunological derangements probably will prevent us from gaining further knowledge in this area of therapeuticsZa razumevanje vloge zdravil za zdravljenje koronavirusne bolezni 19 je pomembno poznati patofiziološko osnovo delitve na zgodnjo fazo bolezni, ko zamejujemo širjenje virusne okužbe, in pozno fazo, ko ugodne izide dosežemo z blaženjem vnetja. Najuspešnejše protivirusne učinkovine so peroralni nirmatrelvir z ritonavirjem ter remdesivir in monoklonska protitelesa proti SARS-CoV-2 za parenteralno uporabo, peroralni molnupiravir pa je manj učinkovit. Najširše preskušeni protivnetni učinkovini sta deksametazon in zaviralec IL-6 tocilizumab. Druge protivnetne učinkovine, baricitinib oz. tofacitinib in anakinra, izkazujejo zelo dobre klinične izide, vendar dokazane le v eni raziskavi. Mutacija virusa v obliko, ki redko povzroča nebrzdano vnetje, pomeni, da verjetno ne bomo dočakali novih uporabnih izidov velikih raziskav na tem področjuTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo